TransCode Therapeutics, Inc.

RNAZ · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$4,856-$4,277-$12,085-$5,916
Dep. & Amort.$5$13$51$123
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$0$158$169
Change in WC$355-$225-$455$942
Other Non-Cash$413$293$9,234$1,536
Operating Cash Flow-$4,083-$4,194-$3,097-$3,146
Investing Activities
PP&E Inv.$0$0$0-$1
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow$0$0$0-$1
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$0$8,855$7,082
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$456$0$0$0
Financing Cash Flow-$456$0$8,855$7,082
Forex Effect$0$0$0$0
Net Chg. in Cash-$4,539-$4,194$5,758$3,935
Supplemental Information
Beg. Cash$7,375$11,569$5,811$1,876
End Cash$2,836$7,375$11,569$5,811
Free Cash Flow-$4,083-$4,194-$3,097-$3,147
TransCode Therapeutics, Inc. (RNAZ) Financial Statements & Key Stats | AlphaPilot